NCT00338273

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: —

Summary

The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.

Conditions

• Bipolar Disorder

Interventions

Type	Name	Description
DRUG	Aripiprazole	Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
DRUG	Placebo	Tablets, Oral, 0 mg, Once daily, 8 weeks.

Timeline

• Start date: 2006-12-01
• Primary completion: 2007-11-01
• Completion: 2007-11-01
• First posted: 2006-06-20
• Last updated: 2013-11-08

Locations

8 sites across 2 countries: United States, India